Clinical Trials Logo

Mantle Cell Lymphoma (MCL) clinical trials

View clinical trials related to Mantle Cell Lymphoma (MCL).

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06043011 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

RUBIN
Start date: September 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

NCT ID: NCT05951959 Recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

TrAVeRse
Start date: December 13, 2023
Phase: Phase 2
Study type: Interventional

TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation. Participants who progress during observation may receive retreatment with acalabrutinib

NCT ID: NCT05720052 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Start date: February 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except malignant lymphoblastic lymphoma (LBL) and Burkitt lymphoma. After the RP2D is identified, Phase II of subjects with relapsed or refractory mantle cell lymphoma who previously received ≥ 2 and ≤ 4 different chemotherapy and/or targeted drug therapy will be enrolled.

NCT ID: NCT05716087 Recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma

Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, multi-center Phase 2 study of oral LP-168 in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.

NCT ID: NCT05665530 Recruiting - T-cell Lymphoma Clinical Trials

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies

Start date: September 12, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib.

NCT ID: NCT05406154 Recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

Start date: December 30, 2020
Phase:
Study type: Observational

This study is a prospective observational clinical trial. A total of 19 research centers were involved in this study. Each site plans to enroll 2-3 patients, and a total of 60 patients will be enrolled. Patients who met the diagnosis of mantle cell lymphoma by histological examination, ECOG (Eastern Oncology Collaborative Group) score 0-2, age >65 years, expected survival of more than 3 months, and at least one measurable lesion were included in this observational clinical trial. In this study, clinical data of patients treated with R-B regimen combined with ibrutinib will be collected, including routine clinical laboratory tests, examinations, and molecular biological data, for efficacy assessment and survival analysis. The main evaluation indicators are the total effective rate of 2 and 6 cycles of alternating R-CHOP/R-DHAP combined with ibrutinib in the treatment of newly treated muff cell lymphoma patients. The 3-year progression-free survival (PFS) and overall survival (OS) of the patients will be assessed, and adverse events to treatment will be collected to evaluate the safety of ibrutinib in combination with untreated mask cell lymphoma.

NCT ID: NCT05131022 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Start date: April 13, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

NCT ID: NCT04186520 Recruiting - Follicular Lymphoma Clinical Trials

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Start date: May 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

NCT ID: NCT03869619 Recruiting - Clinical trials for Follicular Lymphoma (FL)

REal World Data in LYmphoma and Survival in Adults

REALYSA
Start date: November 14, 2018
Phase:
Study type: Observational [Patient Registry]

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to - Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… - Document treatment effectiveness in real life and observance - Address socio-economical questions

NCT ID: NCT03547115 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Start date: May 31, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML